A lethal case of massive hemorrhage after percutaneous liver biopsy in a patient with thrombasthenia.
Complication
Lethal bleeding
Liver biopsy
Thrombasthenia
Journal
Legal medicine (Tokyo, Japan)
ISSN: 1873-4162
Titre abrégé: Leg Med (Tokyo)
Pays: Ireland
ID NLM: 100889186
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
29
06
2023
revised:
27
07
2023
accepted:
14
08
2023
medline:
27
11
2023
pubmed:
21
8
2023
entrez:
20
8
2023
Statut:
ppublish
Résumé
Percutaneous needle liver biopsy is an important procedure in the diagnosis of and assessment of the severity of liver diseases. Although liver biopsy is considered to be a relatively safe procedure, there are occasional cases of death due to massive bleeding after liver biopsy. Thrombasthenia is a disease in which bleeding occurs in the mucosa and skin due to platelet dysfunction. A 60-year-old female was admitted for a liver biopsy for further investigation after an abnormal liver function test. She was diagnosed with thrombasthenia and was being treated with oral tranexamic acid and carbazochrome. Blood tests showed little decrease of platelet count and no abnormalities of blood coagulability. Approximately ten hours after the liver biopsy, the patient complained of nausea and lightheadedness, followed by decreased blood pressure and decreased consciousness. An emergent abdominal CT scan showed a large amount of blood in the abdominal cavity. The patient died despite multidisciplinary treatment, and a forensic autopsy was performed. At internal examination, approximately 2,620 mL of dark red blood was accumulated in the abdominal cavity. A puncture wound led 1.8 cm into the liver from the surface of the liver, and no major vascular damage was observed. The cause of death was considered to be blood loss due to bleeding from the puncture wound. Even if the platelet count is normal, such as in a case of thrombasthenia, the risk of bleeding should not be underestimated. Careful attention should be paid when performing liver biopsy in a patient with risk factors.
Identifiants
pubmed: 37598645
pii: S1344-6223(23)00125-6
doi: 10.1016/j.legalmed.2023.102315
pii:
doi:
Substances chimiques
Tranexamic Acid
6T84R30KC1
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
102315Informations de copyright
Copyright © 2023 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.